Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Current Value
$133.991 Year Return
Current Value
$133.991 Year Return
Market Cap
$21.41B
P/E Ratio
-13.5
1Y Stock Return
44.38%
1Y Revenue Growth
-1.68%
Dividend Yield
0.00%
Price to Book
10.0
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RVTY | 55.14% | $13.38B | +23.61% | 0.26% |
TRMB | 51.14% | $17.01B | +61.09% | 0.00% |
BXP | 48.97% | $12.56B | +48.12% | 4.92% |
BIO | 47.57% | $8.98B | +4.73% | 0.00% |
HHH | 47.37% | $3.98B | +14.89% | 0.00% |
PPBI | 46.96% | $2.67B | +20.00% | 4.75% |
VCYT | 46.92% | $3.03B | +55.48% | 0.00% |
ADPT | 46.91% | $661.15M | +6.16% | 0.00% |
VBTX | 46.87% | $1.58B | +53.68% | 2.75% |
MG | 46.76% | $12.29B | -21.35% | 4.47% |
A | 46.34% | $36.11B | +1.43% | 0.75% |
HOMB | 45.87% | $6.11B | +41.20% | 2.45% |
TMO | 45.74% | $194.74B | +5.54% | 0.30% |
OZK | 45.69% | $5.44B | +17.21% | 3.30% |
ASB | 45.55% | $3.95B | +48.10% | 3.36% |
HWC | 45.46% | $4.92B | +42.32% | 2.46% |
KEY | 45.35% | $18.83B | +58.20% | 4.30% |
TRMK | 45.29% | $2.32B | +69.09% | 2.44% |
LC | 45.08% | $1.69B | +175.00% | 0.00% |
PACB | 45.05% | $471.05M | -79.23% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PBT | -0.02% | $606.38M | -27.11% | 5.87% |
DLNG | 0.04% | $161.93M | +73.23% | 0.00% |
UTI | -0.05% | $1.07B | +73.54% | 0.00% |
GOGL | 0.06% | $2.39B | +35.11% | 8.40% |
LLY | -0.07% | $692.74B | +23.14% | 0.71% |
DELL | -0.12% | $99.00B | +84.60% | 1.24% |
SNCR | -0.15% | $97.34M | +78.17% | 0.00% |
RNR | -0.15% | $13.74B | +23.09% | 0.58% |
CANG | 0.21% | $253.50M | +212.50% | 0.00% |
FLXS | 0.22% | $301.86M | +215.00% | 1.02% |
ATGE | 0.24% | $3.29B | +55.26% | 0.00% |
CHD | 0.26% | $27.18B | +19.50% | 1.03% |
LPTH | 0.29% | $62.27M | +33.05% | 0.00% |
AIZ | -0.32% | $11.24B | +33.00% | 1.31% |
EG | 0.39% | $15.92B | -8.98% | 2.02% |
OHI | 0.42% | $10.84B | +26.02% | 6.71% |
SBLK | 0.44% | $2.38B | +2.30% | 10.64% |
RGA | -0.44% | $14.97B | +41.90% | 1.52% |
WRB | 0.45% | $22.94B | +29.98% | 0.69% |
NHTC | 0.60% | $61.83M | +0.19% | 14.81% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MCK | -17.59% | $78.15B | +35.51% | 0.42% |
PULM | -15.69% | $19.83M | +202.98% | 0.00% |
ABEO | -10.91% | $256.04M | +41.25% | 0.00% |
ACGL | -10.25% | $36.00B | +16.84% | 0.00% |
PGR | -9.36% | $149.10B | +57.29% | 0.45% |
CBOE | -9.16% | $21.46B | +15.84% | 1.11% |
TCTM | -7.33% | $8.10M | -42.99% | 0.00% |
HUSA | -6.60% | $16.69M | -11.56% | 0.00% |
OXBR | -6.45% | $19.05M | +178.18% | 0.00% |
TGS | -5.73% | $1.97B | +116.04% | 0.00% |
LPLA | -5.45% | $23.55B | +38.13% | 0.38% |
MNOV | -5.24% | $93.19M | +2.15% | 0.00% |
NEUE | -4.11% | $40.93M | -34.13% | 0.00% |
VZIO | -3.80% | $2.29B | +67.76% | 0.00% |
BTCT | -3.57% | $42.61M | +353.33% | 0.00% |
AJG | -3.52% | $64.17B | +17.51% | 0.80% |
SYPR | -3.50% | $32.23M | -26.32% | 0.00% |
WHLM | -2.89% | $17.64M | -29.34% | 0.00% |
PRPO | -2.78% | $9.10M | -13.65% | 0.00% |
TEO | -2.60% | $1.69B | +87.97% | 0.00% |
Yahoo
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor typesSALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Re
Yahoo
Kennedy would oversee the National Institutes of Health as head of the Department of Health and Human Services.
SeekingAlpha
Illumina, Inc. (NASDAQ:ILMN) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ETCompany ParticipantsAnkur Dhingra - Chief Financial...
Yahoo
Illumina plans for the global rollout of TruSight Oncology 500 v2, a new version of its NGS cancer assay, by mid-2025.
Yahoo
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Yahoo
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025. Detailed plans for the product will be shared November 21 in a spotlight presentation at the annual meeting of the Association of Molecular Pat
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 60.77% | $70.59M | 0.5% |
FBT | 60.70% | $1.11B | 0.56% |
PBE | 60.24% | $258.53M | 0.58% |
EDOC | 59.66% | $40.86M | 0.68% |
ARKG | 59.36% | $1.13B | 0.75% |
IBB | 57.14% | $6.66B | 0.45% |
FYX | 56.23% | $959.00M | 0.6% |
BBH | 55.65% | $397.87M | 0.35% |
PAWZ | 53.77% | $65.72M | 0.5% |
MOAT | 53.53% | $15.73B | 0.46% |
XRT | 52.90% | $451.85M | 0.35% |
ROBT | 52.54% | $441.35M | 0.65% |
IWN | 52.53% | $13.17B | 0.24% |
RZV | 52.47% | $258.76M | 0.35% |
VIOO | 52.21% | $3.12B | 0.1% |
VBK | 52.16% | $19.31B | 0.07% |
DFSV | 52.14% | $4.16B | 0.31% |
QQQJ | 52.12% | $698.04M | 0.15% |
ESML | 52.06% | $1.90B | 0.17% |
SMMD | 52.02% | $1.24B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -50.34% | $388.04M | 1.43% |
USDU | -25.17% | $201.97M | 0.5% |
VIXY | -24.96% | $195.31M | 0.85% |
UUP | -23.17% | $309.25M | 0.77% |
CTA | -16.39% | $350.27M | 0.78% |
AGZD | -11.12% | $142.76M | 0.23% |
TAIL | -10.26% | $67.98M | 0.59% |
EQLS | -9.74% | $76.08M | 1% |
DBA | -9.41% | $755.88M | 0.93% |
MINT | -9.05% | $11.62B | 0.35% |
KMLM | -8.49% | $353.87M | 0.9% |
IBTE | -8.32% | $1.70B | 0.07% |
BILZ | -5.56% | $563.02M | 0.14% |
KCCA | -4.89% | $220.51M | 0.87% |
CLOI | -4.75% | $715.40M | 0.4% |
JBBB | -3.67% | $1.26B | 0.49% |
TBIL | -3.55% | $4.38B | 0.15% |
CSHI | -1.13% | $482.85M | 0.38% |
WEAT | -0.60% | $120.27M | 0.28% |
HDRO | -0.32% | $164.26M | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TBLL | -0.13% | $1.92B | 0.08% |
HDRO | -0.32% | $164.26M | 0.3% |
IBHD | 0.51% | $327.80M | 0.35% |
DBE | 0.59% | $50.13M | 0.77% |
WEAT | -0.60% | $120.27M | 0.28% |
USCI | 0.93% | $185.47M | 1.07% |
DBO | 0.99% | $217.57M | 0.77% |
SOYB | 1.10% | $27.32M | 0.22% |
CSHI | -1.13% | $482.85M | 0.38% |
FLRN | 1.54% | $2.33B | 0.15% |
JUCY | 1.70% | $324.29M | 0.6% |
XBIL | 1.85% | $637.70M | 0.15% |
FMF | 2.05% | $244.61M | 0.95% |
SHV | 2.28% | $18.13B | 0.15% |
COMT | 2.57% | $829.06M | 0.48% |
CORN | 2.71% | $61.12M | 0.2% |
CANE | 3.55% | $17.72M | 0.29% |
TBIL | -3.55% | $4.38B | 0.15% |
JBBB | -3.67% | $1.26B | 0.49% |
GSG | 3.78% | $914.42M | 0.75% |